Pedinol Pharmacal

Pedinol Pharmacal was a specialty pharmaceutical company focused on the development and commercialization of products for the podiatry and dermatology markets. Established in 1925, the company built a robust portfolio of treatments for foot-related conditions, including fungal infections, nail dystrophy, and dry skin. Key products in its portfolio included Gris-PEG, Penlac, and Nuvail, which addressed significant needs in foot and ankle care. The company operated as a family-owned business for decades, establishing a strong reputation among podiatric physicians. In 2012, Pedinol was acquired by Valeant Pharmaceuticals (now Bausch Health) for approximately 13 million USD. This acquisition allowed Valeant to expand its presence in the podiatry segment and leverage Pedinol's established sales force and product line.